APOO Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the APOO gene has been disrupted to create a loss-of-function model for mitochondrial biology studies. This polyclonal pool contains diverse APOO mutations across the cell population, enabling functional investigation of Apolipoprotein O in cristae organization and apoptosis without clonal selection.
HAP1 is a near-haploid human cell line derived from KBM-7 chronic myeloid leukemia cells. Its near-haploid karyotype simplifies genetic analysis by eliminating allelic variation, making it ideal for functional genomics and CRISPR-based screens. HAP1 cells maintain essential cellular pathways and provide a robust platform for generating gene knockouts, facilitating the study of gene function in a human context.
Apolipoprotein O (APOO) is a mitochondrial inner membrane protein that associates with the MICOS complex, interacting with MIC19, MIC60, and OPA1 to sustain cristae junction integrity and oxidative phosphorylation. APOO is regulated by PGC-1??, PPAR??, and SIRT3, and its loss disrupts cristae architecture, leading to cytochrome c release, activation of BAX and BAK, and reduced mitochondrial membrane potential. APOO also interacts with cardiolipin and SAM50, implicating it in lipid metabolism and membrane organization.
In the near-haploid HAP1 background, APOO knockout provides a clear loss-of-function readout without the confounding influence of a second functional allele, enhancing its utility for high-content genetic screens and metabolic assays. The polyclonal nature of the knockout pool captures the heterogeneity of CRISPR-induced editing, allowing population-level analyses that better mimic physiological variability while enabling straightforward assessment of mitochondrial phenotypes.
These knockout cells are suitable for mitochondrial biology and apoptosis research using Western blotting and immunofluorescence to examine MICOS complex components and cristae morphology. They support metabolic flux analysis via Seahorse assays and flow cytometry for mitochondrial membrane potential, as well as co-immunoprecipitation to probe APOO interactions. Applications include metabolic disease modeling, cancer metabolism studies, and drug target validation. For further information, contact Ascent Research.
